Nkarta, Inc. (NKTX)
NASDAQ:NKTX
Want to see NKTX full AI Analyst Report?
NKTX Stock Chart & Stats
$3.47
-$0.05(-2.07%)
At close: 4:00 PM EST
$3.47
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.63 - $3.65
Previous CloseN/A
Volume369.36K
Average Volume (3M)576.17K
Market Cap
$204.62M
Enterprise Value$236.52M
Total Cash (Recent Filing)$230.43M
Total Debt (Recent Filing)$75.00M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding71,545,360
10 Day Avg. Volume576,011
30 Day Avg. Volume576,166
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-101.08
Enterprise Value/Ebitda-2.61
Forecast
1Y Price Target
$11.80Price Target Upside240.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageSustained moderate leverage indicates the company is not over-reliant on debt to fund operations, preserving flexibility for additional R&D or strategic investments. This reduces near-term bankruptcy risk and supports ability to raise capital without excessive interest burdens over the next several quarters.
Strategic Industry PartnershipA material collaboration with Roche/Genentech provides durable scientific validation, potential shared development resources, and optional downstream commercialization support. Such partnerships can de-risk clinical development and improve access to regulatory and commercial expertise over multiple development cycles.
Improved Corporate GovernanceStronger governance and regularized shareholder oversight enhance board accountability and audit quality, reducing governance-related execution risk. Annual say-on-pay and a ratified auditor signal commitment to transparency, which supports credibility with investors and potential partners over time.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow at ~-80M to -90M TTM implies ongoing reliance on external financing to sustain R&D and operations. This structural burn rate increases dilution risk and creates execution pressure to achieve clinical or partnership milestones before cash exhaustion.
Pre-revenue ProfileAbsence of product revenue means the business depends on milestones, partnerships, or financing for value realization. For a clinical-stage biotech, this limits cash resilience and makes long-term viability contingent on successful trials, regulatory approvals, or durable licensing deals.
Eroding Shareholder EquitySteady declines in equity reflect cumulative losses and capital consumption, signaling diminishing financial cushion. That trend heightens the need for capital markets access and increases the probability of dilutive financings, constraining long-term return potential for existing shareholders.
Nkarta News
NKTX FAQ
What was Nkarta, Inc.’s price range in the past 12 months?
Nkarta, Inc. lowest stock price was $1.63 and its highest was $3.65 in the past 12 months.
What is Nkarta, Inc.’s market cap?
Nkarta, Inc.’s market cap is $204.62M.
When is Nkarta, Inc.’s upcoming earnings report date?
Nkarta, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Nkarta, Inc.’s earnings last quarter?
Nkarta, Inc. released its earnings results on May 12, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.016.
Is Nkarta, Inc. overvalued?
According to Wall Street analysts Nkarta, Inc.’s price is currently Undervalued.
Does Nkarta, Inc. pay dividends?
Nkarta, Inc. does not currently pay dividends.
What is Nkarta, Inc.’s EPS estimate?
Nkarta, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Nkarta, Inc. have?
Nkarta, Inc. has 71,545,360 shares outstanding.
What happened to Nkarta, Inc.’s price movement after its last earnings report?
Nkarta, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -6.707%.
Which hedge fund is a major shareholder of Nkarta, Inc.?
Currently, no hedge funds are holding shares in NKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (240.06% Upside)
$11.80 (240.06% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 846.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.14%
12-Months-Change
Fundamentals
Return on Equity
-30.90%
Trailing 12-Months
Asset Growth
-20.94%
Trailing 12-Months
Company Description
Nkarta, Inc.
Nkarta, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to advancing and marketing cell-based treatments for cancer. Their innovative cellular immunotherapy strategy outfits natural killer (NK) cells with chimeric antigen receptors (CARs) on their surface, allowing these cells to pinpoint particular proteins or antigens found on the exterior of tumor cells. The company's primary investigational products include NKX101, which is undergoing Phase I human trials for resistant or recurring acute myeloid leukemia and high-risk myelodysplastic syndromes. Another key candidate is NKX019, a pre-clinical asset designed to combat various B-cell malignancies by targeting the CD19 antigen present on these cancerous cells. Furthermore, Nkarta maintains a collaborative research partnership with CRISPR Therapeutics AG. Founded in 2015, the company's main operations are situated in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(240.06% Upside)
Technical Analysis
Ownership Overview
20.64% Insiders
7.56% Mutual Funds
48.74% Other Institutional Investors
16.34% Public Companies and
Individual Investors